Published in J Clin Invest on September 01, 2011
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. Front Immunol (2012) 0.98
Novel immunoregulatory role of perforin-positive dendritic cells. Semin Immunopathol (2016) 0.83
Allergy: Peaceful death ends pain. Nat Rev Immunol (2011) 0.75
Treatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features. Front Immunol (2016) 0.75
Early-Life Nutritional Factors and Mucosal Immunity in the Development of Autoimmune Diabetes. Front Immunol (2017) 0.75
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
Taking dendritic cells into medicine. Nature (2007) 11.82
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell (1996) 8.89
Adaptive immune features of natural killer cells. Nature (2009) 8.46
T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol (2006) 6.23
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
The tumor necrosis factor ligand and receptor families. N Engl J Med (1996) 4.49
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol (2007) 4.29
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature (1994) 3.34
The CD8+ dendritic cell subset. Immunol Rev (2010) 3.32
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol (2007) 2.92
Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci U S A (1992) 2.77
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med (2007) 2.47
Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci U S A (2002) 2.45
Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity (2004) 2.36
Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity (2005) 2.35
TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov (2010) 2.17
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med (2000) 2.00
Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity (2005) 1.99
A crucial role for p80 TNF-R2 in amplifying p60 TNF-R1 apoptosis signals in T lymphocytes. Eur J Immunol (2000) 1.89
Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci (2002) 1.88
Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity (1999) 1.86
Mast cell-associated TNF promotes dendritic cell migration. J Immunol (2006) 1.78
Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity (2001) 1.53
Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J Immunol (1997) 1.43
Function and regulation of tumor necrosis factor receptor type 2. Curr Med Chem (2004) 1.40
Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J Immunol (2008) 1.36
Natural killer or dendritic: what's in a name? Immunity (2007) 1.32
Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun (2010) 1.29
TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol (2006) 1.29
A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol (2002) 1.26
Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75. J Immunol (1997) 1.23
TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol (1998) 1.23
Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol (1995) 1.11
Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood (2010) 1.10
Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology (2007) 1.03
Cooperation of both TNF receptors in inducing apoptosis: involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. J Immunol (1998) 1.02
Expression and function of TNF and IL-1 receptors on human regulatory T cells. PLoS One (2010) 1.01
TNF receptor 2-deficient CD8 T cells are resistant to Fas/Fas ligand-induced cell death. J Immunol (2000) 1.01
Low zone tolerance to contact allergens in mice: a functional role for CD8+ T helper type 2 cells. J Exp Med (1996) 1.00
TNF-alpha-induced apoptosis in human naïve and memory CD8+ T cells in aged humans. Exp Gerontol (2005) 0.88
New aspects of the molecular basis of contact allergy. Curr Opin Allergy Clin Immunol (2007) 0.86
Critical role of IL-10 in the induction of low zone tolerance to contact allergens. J Clin Invest (2003) 0.86
B cells are not required for T cell priming in low zone tolerance to contact allergens and contact hypersensitivity. Eur J Immunol (2004) 0.82
Low zone tolerance induced by systemic application of allergens inhibits Tc1-mediated skin inflammation. J Allergy Clin Immunol (2006) 0.81
Induction of low zone tolerance to contact allergens in mice does not require functional Langerhans cells. J Invest Dermatol (1996) 0.79
Development of allergic contact dermatitis requires activation of both tumor necrosis factor-receptors. Eur Cytokine Netw (2001) 0.77
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med (2010) 2.98
IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med (2007) 2.00
High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol (2009) 1.98
WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J (2012) 1.96
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol (2013) 1.91
Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature (2004) 1.91
A beneficial role for immunoglobulin E in host defense against honeybee venom. Immunity (2013) 1.71
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol (2011) 1.64
Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. J Allergy Clin Immunol (2009) 1.60
Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J (2012) 1.58
Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol (2007) 1.54
Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol (2006) 1.53
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol (2009) 1.51
Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol (2004) 1.51
Mast cells are required for normal healing of skin wounds in mice. FASEB J (2006) 1.50
Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy (2009) 1.49
Mast cells--key effector cells in immune responses. Trends Immunol (2007) 1.48
Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges (2009) 1.40
TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood (2005) 1.39
Migration of melanoblasts into the developing murine hair follicle is accompanied by transient c-Kit expression. J Histochem Cytochem (2002) 1.26
Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med (2008) 1.23
Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J (2006) 1.21
International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol (2012) 1.17
Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol (2005) 1.16
Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J Clin Invest (2011) 1.16
Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol (2010) 1.15
Physical urticaria. Curr Allergy Asthma Rep (2012) 1.14
Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood (2007) 1.10
IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? PLoS One (2011) 1.10
Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol (2007) 1.10
Immediate contact skin reactions, an update of Contact Urticaria, Contact Urticaria Syndrome and Protein Contact Dermatitis -- "A Never Ending Story". Eur J Dermatol (2010) 1.09
Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol (2007) 1.07
Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proc Natl Acad Sci U S A (2012) 1.05
Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol (2013) 1.05
Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol (2011) 1.04
Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol (2011) 1.04
Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol (2012) 1.03
Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp Dermatol (2009) 1.02
Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol (2013) 1.02
Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am (2013) 1.02
Mast cell functions in the innate skin immune system. Immunobiology (2007) 1.01
Innate immunity and allergy in the skin. Curr Opin Immunol (2009) 1.00
Mast cells: makers and breakers of allergic inflammation. Curr Opin Allergy Clin Immunol (2009) 1.00
Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol (2006) 0.99
Kit is expressed by epithelial cells in vivo. J Invest Dermatol (2003) 0.98
Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol (2010) 0.97
Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. J Allergy Clin Immunol (2007) 0.96
Inflammatory murine skin responses to UV-B light are partially dependent on endothelin-1 and mast cells. Am J Pathol (2006) 0.96
Interleukin-10-treated dendritic cells modulate immune responses of naive and sensitized T cells in vivo. J Invest Dermatol (2002) 0.96
Tolerogenic dendritic cells in health and disease: friend and foe! Eur J Dermatol (2007) 0.94
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. J Invest Dermatol (2014) 0.94
Update on chronic urticaria: focusing on mechanisms. Curr Opin Allergy Clin Immunol (2008) 0.93
The role of interleukin-1 in allergy-related disorders. Curr Opin Allergy Clin Immunol (2012) 0.93
Interferon-α suppresses cAMP to disarm human regulatory T cells. Cancer Res (2013) 0.93
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J (2011) 0.93
Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol (2011) 0.91
Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol (2011) 0.90
Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol (2014) 0.90
High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol (2011) 0.90
Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy Asthma Proc (2016) 0.90
Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol (2010) 0.89
Dendritic cells: sentinels of immunity and tolerance. Int J Hematol (2005) 0.88
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy (2011) 0.88
Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells. Exp Dermatol (2008) 0.88
Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol (2007) 0.87
Critical role of IL-10 in the induction of low zone tolerance to contact allergens. J Clin Invest (2003) 0.86
Successful treatment of adult multisystemic Langerhans cell histiocytosis with psoralen-UV-A, prednisolone, mercaptopurine, and vinblastine. Arch Dermatol (2008) 0.86
Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg (2012) 0.86
MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle (2007) 0.85
CD40 signalling induces IL-10-producing, tolerogenic dendritic cells. Exp Dermatol (2009) 0.85
The majority of brain mast cells in B10.PL mice is present in the hippocampal formation. Neurosci Lett (2005) 0.85
Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur J Immunol (2003) 0.85
NMR solution structure and dynamics of the peptidyl-prolyl cis-trans isomerase domain of the trigger factor from Mycoplasma genitalium compared to FK506-binding protein. J Mol Biol (2002) 0.84
Role and relevance of mast cells in fungal infections. Front Immunol (2012) 0.84
Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol (2007) 0.84
Cardioprotective C-kit⁺ bone marrow cells attenuate apoptosis after acute myocardial infarction in mice - in-vivo assessment with fluorescence molecular imaging. Theranostics (2013) 0.84
Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Rev Clin Immunol (2011) 0.83
Fasciola hepatica tegumental coat impairs mast cells' ability to drive Th1 immune responses. J Immunol (2013) 0.83
Modern approaches to the diagnosis and treatment of cold contact urticaria. Curr Allergy Asthma Rep (2010) 0.83
Histamine and antihistamines in atopic dermatitis. Adv Exp Med Biol (2010) 0.83
Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey. Allergy Asthma Proc (2015) 0.83